Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 5Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Radiation Pneumonitis 2Peritoneal Neoplasms 2Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophagogastric Adenocarcinoma 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Pemetrexed 12Cisplatin 11pembrolizumab 8Carboplatin 6Ipilimumab 5Nivolumab 4LMB-100 4durvalumab 3Gemcitabine 3tremelimumab 2tazemetostat 2anetumab ravtansine 2Vinorelbine 2Plicamycin 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2vandetanib 1tocilizumab 1spartalizumab 1ribociclib 1rebastinib 1pevonedistat 1olaparib 1niraparib 1nintedanib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mesothelioma × nintedanib × Clear all
NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated
545 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡